Aldeyra provides reproxalap trial endpoint estimates and FDA stance in corporate overview

Aldeyra Therapeutics, Inc.

• Standardized treatment estimates and confidence intervals disclosed for reproxalap dry eye disease clinical trials primary endpoints.
• Aldeyra summarizes its interpretations of FDA positions on primary endpoints and its own positions in the NDA.
• Presentation is a voluntary Reg FD disclosure; no financial results or guidance included.